Definitive radiotherapy or chemoradiotherapy for distal rectal cancer with early stage of cT1-2N0
Cancer Management and Research Jun 14, 2019
Peng HH, et al. - In this retrospective analysis of patients treated for distal rectal cancer with stage cT1-2N0 (n=231), researchers assessed the role of definitive external beam radiotherapy or chemoradiotherapy as treatment options. Clinical complete response (cCR) was achieved by 135 patients (58.4%), for the whole group. The estimated 5-year overall survival, progression-free survival (PFS), and local recurrence-free survival were 86.19%, 83.30%, and 92.50%, respectively. Better survival was experienced by patients with cCR vs those with non-cCR. Independent predictors of PFS were clinical stage, carcinoembryonic antigen and concurrent chemotherapy, in multivariable analysis. In some early-stage distal rectal cancer, possible feasibility of definitive radiotherapy or chemoradiotherapy is suggested regarding its favorable efficacy.
Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
-
Exclusive Write-ups & Webinars by KOLs
-
Daily Quiz by specialty
-
Paid Market Research Surveys
-
Case discussions, News & Journals' summaries